Does tumor necrosis factor-α (TNF-α) contribute to myocardial reperfusion injury in anesthetized rats?

General Pharmacology

Volumn 32, Issue 1, 1999, Pages 41-45

  McVey, Matthew ^a   Perrone, Mark H ^a   Clark, Kenneth L ^a  

^a Rhone Poulenc Rorer 500 Arcola Rd ^*  (United States)

Author keywords

Anesthetized rat; Ischemic preconditioning; Myocardial infarction; PDE IV inhibition; Rolipram; TNF

Indexed keywords

PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANESTHESIA; ANIMALS; BLOOD PRESSURE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032889831     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00050-0     Document Type: Article

References (23)

1. Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor α production by phosphodiesterase inhibitors. J. Pharmac. Exp. Ther. 279:1996;247-254.
2. Chiu N., Park I., Reid I.A. Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram. J. Pharmac. Exp. Ther. 276:1996;1073-1077.
3. Field G., Conn C.A., McClanahan T.B., Nao B.S., Kluger M.J., Gallagher K.P. Tumor necrosis factor and interleukin-6 are not elevated in venous blood from ischemic canine myocardium. Proc. Soc. Exp. Biol. Med. 206:1994;384-391.
4. Granger D.N., Korthuis R.J. Physiologic mechanisms of postischemic tissue injury. Ann. Rev. Physiol. 57:1995;311-332.
5. Gurevitch J., Frolkis I., Yuhas Y., Paz Y., Matsa M., Mohr R., Yakirevich V. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J. Am. Coll. Cardiol. 28:1996;247-252.
6. Gurevitch J., Frolkis I., Yuhas Y., Lifschitz-Mercer B., Berger E., Paz Y., Matsa M., Kramer A., Mohr R. Anti-tumor necrosis factor alpha improves myocardial recovery after ischemia and reperfusion. J. Am. Coll. Cardiol. 30:1997;1554-1561.
7. Hansen P.R. Myocardial reperfusion injury. experimental evidence and clinical relevance Eur. Heart J. 16:1995;734-740.
8. Hearse D.J., Bolli R. Reperfusion induced injury. Manifestations, mechanisms and clinical relevance. Trends Cardiovasc. Med. 1:1991;233-240.
9. Herskowitz A., Choi S., Ansari A.A., Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am. J. Pathol. 146:1995;419-428.
10. Jansen N.J.G., van Oeveren W., Gu Y.J., van Vliet M.H., Eijsman L., Wildevuur C.R.H. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann. Thorac. Surg. 54:1992;744-748.
11. Maury C.P.J., Teppo A.M. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. J. Int. Med. 225:1989;333-336.
12. 99mTc Sestamibi imaging predicts subsequent mortality. Circulation. 92:1995;334-341.
13. Molnar-Kimber K., Yonno L., Heaslip R., Weichman B. Modulation of TNF-α and IL-1β from endotoxin stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions. 39:1993;C77-C79.
14. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia. a delay of lethal cell injury in ischemic myocardium Circulation. 74:1986;1124-1136.
15. Nicholson C.D., Challiss R.A.J., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TIPS. 12:1991;19-27.
16. Pang X., Hershman J.M., Chung M., Pekary A.E. Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyotrophin. Endocrinology. 125:1989;1783-1788.
17. Prabhakar U., Lipshutz D., O'Leary Bartus J., Slivjak M.J., Smith E.F. III, Lee J.C., Esser K.M. Characterization of cAMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmac. 16:1994;805-816.
18. Reeves M.L., Leigh B.K., England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem. J. 241:1987;535-541.
19. Semmler J., Wachtel H., Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmac. 15:1993;409-413.
20. Shahid M., Nicholson C.D. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium. positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram Naunyn-Schmiedeberg's Arch. Pharmac. 342:1990;698-705.
21. Simpson P.J., Schelm J.A., Smallwood J.K., Clay M.P., Lindstrom T.D. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury. J Cardiovasc. Pharmac. 19:1992;987-995.
22. Squadrito F., Altavilla D., Zingarelli B., Ioculano M., Calapai G., Campo G.M., Miceli A., Caputi A.P. Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury. Eur. J. Pharmac. 237:1993;223-230.
23. Van Bladel S., Libert C., Fiers W. Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes. Cytokine. 3:1991;149-154.